Option chain shows key data for Lee's Pharmaceutical Hldg's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lee's Pharmaceutical Hldg.

Lee's Pharmaceutical Hldg (OTC:LPCUF) Stock, Option Chain

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Biotech

Penny Stocks

General

AKBA

LPCUF

UNCY

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive.

LEES PHARMA HLDGS LTD ORD by Lees Pharmaceutical Holdings Ltd

Comments

Lee's Pharmaceutical Hldg

Lee's Pharmaceutical Hldg (LPCUF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga